קפיטליזציית שוק: TransMedics Group (TMDX)

TransMedics Group (TMDX) generates revenue through the sale of mobile organ preservation systems and associated consumables. The company mitigates operational risks by developing its own aviation logistics and expanding the range of supported organs. The current metric stands at 2.51. Due to patent protection and strict FDA regulations, the company maintains a monopoly, as evidenced by the price trajectory of the securities shown below.

Market capitalization reflects the total value of equity through the balance of supply and demand, determining the real-time market valuation of the business. The current market capitalization of TransMedics Group (TMDX) confirms investor confidence in the expansion rates of organ preservation systems and logistical precision, transforming high revenue growth into sustainable investment attractiveness for the asset.